论文信息 - Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). - 字舞流文

Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET).

F. Meric-Bernstam | A. Phan | J. Mares | D. Chang | J. Yao | A. Rashid | C. Jacobs | Jun Yao | J. Mares | David Z. Chang